<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7551450\results\search\disease\results.xml">
  <result pre="[3], and a global pandemic of COVID-19 caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was eventually declared by"/>
  <result pre="and a global pandemic of COVID-19 caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was eventually declared by the"/>
  <result pre="a global pandemic of COVID-19 caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was eventually declared by the World"/>
  <result pre="and on researching other ways to identify and manage the" exact="disease" post="and limit its onward transmission [5,9], thereby reducing the"/>
  <result pre="be conducted in the fields of pathogen monitoring, source identification," exact="primary" post="etiology, clinical treatments, vaccine development, viral replication, pathogenesis, antiviral"/>
  <result pre="pathogen monitoring, source identification, primary etiology, clinical treatments, vaccine development," exact="viral" post="replication, pathogenesis, antiviral drugs, and others [9,10,11]. The US"/>
  <result pre="also makes significant contributions to ongoing publicly shared research in" exact="disease" post="transmission, diagnostics, vaccine development, and therapeutics, as well as"/>
  <result pre="improve the efficiency of the allocation of the funding for" exact="infectious" post="disease-related R&amp;amp;D, it is necessary to understand the current"/>
  <result pre="and its other agencies, such as the Korea Center for" exact="Disease" post="Control (KCDC), have made saving lives their highest priority"/>
  <result pre="Due to the magnitude of the public funds invested in" exact="infectious" post="disease-related research [14], the Korean government has to evaluate"/>
  <result pre="To date, few studies have provided a comprehensive analysis of" exact="infectious disease" post="R&amp;amp;D from a public funding perspective [13,14,15]. To the"/>
  <result pre="date, few studies have provided a comprehensive analysis of infectious" exact="disease" post="R&amp;amp;D from a public funding perspective [13,14,15]. To the"/>
  <result pre="have critical roles in the scientific and technological advancements in" exact="infectious diseases" post="[14,19,20]. In particular, as the four leading national scientific"/>
  <result pre="utilized in many studies of Korean R&amp;amp;D trends [23,24,25]. A" exact="total" post="of 599 and 638 nationally funded R&amp;amp;D projects related"/>
  <result pre="Further Analysis None of the national R&amp;amp;D databases provide the" exact="complete" post="information of all nationally funded projects. For example, suppose"/>
  <result pre="fiscal years, which did not allow us to estimate the" exact="total" post="amount of funds for multi-year projects. Thus, calculations were"/>
  <result pre="of these projects in the global R&amp;amp;D database and the" exact="total" post="period (year) of these projects. After that, we removed"/>
  <result pre="these projects from other data sources. Table 1 shows a" exact="total" post="of 273 and 170 nationally funded R&amp;amp;D projects related"/>
  <result pre="as follows: (Cluster 1) research on the molecular characteristics of" exact="infectious" post="viruses and the interaction mechanisms of viral pathogens and"/>
  <result pre="molecular characteristics of infectious viruses and the interaction mechanisms of" exact="viral" post="pathogens and human hosts, including the immune response, for"/>
  <result pre="research related to the platform for the immunological response to" exact="viral infection" post="and for vaccine development; (Sub-Cluster 1-3) the platform for"/>
  <result pre="related to the platform for the immunological response to viral" exact="infection" post="and for vaccine development; (Sub-Cluster 1-3) the platform for"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins; and (Cluster 3) infectious disease"/>
  <result pre="function of viral and human receptor proteins; and (Cluster 3)" exact="infectious disease" post="epidemiological investigation and animal and environmental ecology (all of"/>
  <result pre="of viral and human receptor proteins; and (Cluster 3) infectious" exact="disease" post="epidemiological investigation and animal and environmental ecology (all of"/>
  <result pre="for each cluster. 3.1.1. Research on the Molecular Characteristics of" exact="Infectious" post="Viruses and the Interaction Mechanism of Viral Pathogens and"/>
  <result pre="Molecular Characteristics of Infectious Viruses and the Interaction Mechanism of" exact="Viral" post="Pathogens and Human Hosts, Including the Immune Response, for"/>
  <result pre="against COVID-19 (Cluster 1) Research on the molecular characteristics of" exact="infectious" post="viruses and the interaction mechanism of viral pathogens and"/>
  <result pre="molecular characteristics of infectious viruses and the interaction mechanism of" exact="viral" post="pathogens and human hosts, including the immune response, for"/>
  <result pre="a project called â€œHost, pathogen, and the microbiome: determinants of" exact="infectious disease" post="outcomesâ€� and spent 19.6 million USD between 2014 and"/>
  <result pre="project called â€œHost, pathogen, and the microbiome: determinants of infectious" exact="disease" post="outcomesâ€� and spent 19.6 million USD between 2014 and"/>
  <result pre="a project entitled â€œEuropean management platform for emerging and reemerging" exact="infectious disease" post="entitiesâ€� with expenditures of 18.6 million USD between 2009"/>
  <result pre="project entitled â€œEuropean management platform for emerging and reemerging infectious" exact="disease" post="entitiesâ€� with expenditures of 18.6 million USD between 2009"/>
  <result pre="research related to the platform for an immunological response to" exact="viral infection" post="and vaccine development (Sub-Cluster 1-2) was comprised of 38"/>
  <result pre="related to the platform for an immunological response to viral" exact="infection" post="and vaccine development (Sub-Cluster 1-2) was comprised of 38"/>
  <result pre="10 year project wraps up in 2022. The New York" exact="Blood" post="Center committed to spending 4.5 million USD on a"/>
  <result pre="vaccinesâ€� between 2018 and 2023. Meanwhile, The National Institute of" exact="Infectious" post="Diseases of Japan finished a vaccine project costing 144,300"/>
  <result pre="between 2018 and 2023. Meanwhile, The National Institute of Infectious" exact="Diseases" post="of Japan finished a vaccine project costing 144,300 USD"/>
  <result pre="million USD project entitled â€œDiagnostic and prognostic biomarkers for severe" exact="viral" post="lung diseaseâ€� between 2014 and 2019. Meanwhile, Erasmus Universitair"/>
  <result pre="Japan completed its study â€œEstablishment of gene diagnosis of feline" exact="infectious" post="peritonitis by the analysis of the viral genomeâ€� with"/>
  <result pre="completed its study â€œEstablishment of gene diagnosis of feline infectious" exact="peritonitis" post="by the analysis of the viral genomeâ€� with expenditures"/>
  <result pre="diagnosis of feline infectious peritonitis by the analysis of the" exact="viral" post="genomeâ€� with expenditures of 132,600 USD (see Table 4)."/>
  <result pre="132,600 USD (see Table 4). 3.1.2. Research on the Virus" exact="Protein" post="Structure, Activity/Function-Based Antivirus Therapeutics (Treatment) Design, and Activity/Resistance Modulation"/>
  <result pre="included six projects totaling 6,911,261 USD. In the US, The" exact="Blood" post="Systems Research Institute joined a 2 million USD project,"/>
  <result pre="Systems Research Institute joined a 2 million USD project, â€œModeling" exact="viral" post="entry and its inhibition using SARS-CoVâ€�, between 2007 and"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins (Sub-Cluster 2-2) included 31 projects"/>
  <result pre="144,000 USD between 2016 and 2019 (see Table 6). 3.1.3." exact="Infectious" post="Disease Epidemiological Investigation and Animal and Environmental Ecology (Cluster"/>
  <result pre="USD between 2016 and 2019 (see Table 6). 3.1.3. Infectious" exact="Disease" post="Epidemiological Investigation and Animal and Environmental Ecology (Cluster 3)"/>
  <result pre="Disease Epidemiological Investigation and Animal and Environmental Ecology (Cluster 3)" exact="Infectious" post="disease epidemiological investigation and animal and environmental ecology (Cluster"/>
  <result pre="Epidemiological Investigation and Animal and Environmental Ecology (Cluster 3) Infectious" exact="disease" post="epidemiological investigation and animal and environmental ecology (Cluster 3)"/>
  <result pre="between 2018 and 2023. In Japan, the National Institute of" exact="Infectious" post="Diseases recently completed â€œThe survey of middle east respiratory"/>
  <result pre="2018 and 2023. In Japan, the National Institute of Infectious" exact="Diseases" post="recently completed â€œThe survey of middle east respiratory syndrome"/>
  <result pre="of Infectious Diseases recently completed â€œThe survey of middle east" exact="respiratory" post="syndrome coronavirus of the dromedary in Ethiopiaâ€� project with"/>
  <result pre="Infectious Diseases recently completed â€œThe survey of middle east respiratory" exact="syndrome" post="coronavirus of the dromedary in Ethiopiaâ€� project with total"/>
  <result pre="respiratory syndrome coronavirus of the dromedary in Ethiopiaâ€� project with" exact="total" post="expenditures of 413,400 USD between 2017 and 2020 (see"/>
  <result pre="Projects of Korea 3.2.1. Research on the Molecular Characteristics of" exact="Infectious" post="Viruses and the Interaction Mechanisms of Viral Pathogens and"/>
  <result pre="Molecular Characteristics of Infectious Viruses and the Interaction Mechanisms of" exact="Viral" post="Pathogens and Human Hosts, Including the Immune Response, for"/>
  <result pre="Korea (Cluster 1) Overall, research on the molecular characteristics of" exact="infectious" post="viruses and the interaction mechanisms of viral pathogens and"/>
  <result pre="molecular characteristics of infectious viruses and the interaction mechanisms of" exact="viral" post="pathogens and human hosts, including immune responses, for developing"/>
  <result pre="research related to the platform for the immunological response to" exact="viral infection" post="and for vaccine development in Korea (Sub-Cluster 1-2) is"/>
  <result pre="related to the platform for the immunological response to viral" exact="infection" post="and for vaccine development in Korea (Sub-Cluster 1-2) is"/>
  <result pre="project on â€œThe development of therapeutic antibodies against Middle Eastern" exact="respiratory" post="syndrome coronavirus and Zika virusâ€� with spending totaling near"/>
  <result pre="on â€œThe development of therapeutic antibodies against Middle Eastern respiratory" exact="syndrome" post="coronavirus and Zika virusâ€� with spending totaling near 500,000"/>
  <result pre="customized genetic engineering technology-based approaches for the control of disastrous" exact="infectious" post="diseasesâ€� in 2017, which is expected to finish in"/>
  <result pre="in 2017, which is expected to finish in 2026 with" exact="total" post="expenditures of 477,328 USD. Meanwhile, The Korea Research Institute"/>
  <result pre="and 2021 (see Table 10). 3.2.2. Research on the Virus" exact="Protein" post="Structure, Activity/Function-Based Antivirus Therapeutics (Treatment) Design, and Activity/Resistance Modulation"/>
  <result pre="Biotechnology has committed to funding a project entitled â€œDevelopment of" exact="viral" post="recombination prediction and validation technique using bioinformaticsâ€� with projected"/>
  <result pre="2006 and 2009. Meanwhile, Kyungdon Universityâ€™s project, â€œBig-data analysis on" exact="viral infection" post="using epigenetic informationâ€�, spent 144,475 USD between 2016 and"/>
  <result pre="and 2009. Meanwhile, Kyungdon Universityâ€™s project, â€œBig-data analysis on viral" exact="infection" post="using epigenetic informationâ€�, spent 144,475 USD between 2016 and"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins in Korea (Sub-Cluster 2-2) were"/>
  <result pre="candidates for the development of therapeutics in the Middle East" exact="Respiratory" post="Syndromeâ€�, with budgeted expenditures of 763,636 and â€œDevelopment therapeutic"/>
  <result pre="â€œDevelopment therapeutic target and candidate for immunotherapy against middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV)â€� with a budget of 418,182 USD"/>
  <result pre="therapeutic target and candidate for immunotherapy against middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV)â€� with a budget of 418,182 USD between"/>
  <result pre="USD between 2016 and 2021, respectively (see Table 12). 3.2.3." exact="Infectious" post="Disease Epidemiological Investigation and Animal and Environmental Ecology in"/>
  <result pre="between 2016 and 2021, respectively (see Table 12). 3.2.3. Infectious" exact="Disease" post="Epidemiological Investigation and Animal and Environmental Ecology in Korea"/>
  <result pre="Investigation and Animal and Environmental Ecology in Korea (Cluster 3)" exact="Infectious" post="disease epidemiological investigation and animal and environmental ecology in"/>
  <result pre="and Animal and Environmental Ecology in Korea (Cluster 3) Infectious" exact="disease" post="epidemiological investigation and animal and environmental ecology in Korea"/>
  <result pre="The US has a wide range of research fields for" exact="infectious disease" post="preparedness ranging from basic research (i.e., the identification and"/>
  <result pre="US has a wide range of research fields for infectious" exact="disease" post="preparedness ranging from basic research (i.e., the identification and"/>
  <result pre="from basic research (i.e., the identification and mechanism of the" exact="viral" post="pathogen) (62.0%) to animalâ€&quot;environmental ecology and the epidemiologic investigation"/>
  <result pre="to animalâ€&quot;environmental ecology and the epidemiologic investigation and quarantine of" exact="infectious diseases" post="(23.8%) and has invested from a mid- to long-term"/>
  <result pre="1-2: 45.4%, and Sub-Cluster 1-3: 29.3%), including the identification of" exact="infectious disease" post="pathogens, the structure and replication mechanism of viruses, infection"/>
  <result pre="45.4%, and Sub-Cluster 1-3: 29.3%), including the identification of infectious" exact="disease" post="pathogens, the structure and replication mechanism of viruses, infection"/>
  <result pre="infectious disease pathogens, the structure and replication mechanism of viruses," exact="infection" post="mechanisms in the host, and immune responses, which are"/>
  <result pre="research related to the platform for the immunological response to" exact="viral" post="infections and for vaccine development (Sub-Cluster 1-2: Korea: 45.4%"/>
  <result pre="related to the platform for the immunological response to viral" exact="infections" post="and for vaccine development (Sub-Cluster 1-2: Korea: 45.4% vs."/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins (Sub-Cluster 2-2: Korea: 14.3% vs."/>
  <result pre="remain a priority. Thus, the Korean government must confront the" exact="deficiency" post="of their capabilities in core technology areas rather than"/>
  <result pre="leading organizations. In particular, it is necessary to develop the" exact="infectious" post="disease-related basic research, diagnostics, vaccines, and therapeutics where Koreaâ€™s"/>
  <result pre="to investigate the status quo of the R&amp;amp;D of global" exact="infectious diseases" post="in order to improve global cooperation strategies, with more"/>
  <result pre="support through funding the R&amp;amp;D of technologies that deal with" exact="infectious diseases." post="Further study is needed on the analysis of R&amp;amp;D"/>
  <result pre="virology, recognized as a basic research area for battling against" exact="infectious diseases" post="more effectively, and its associated disciplines to strengthen the"/>
  <result pre="and its associated disciplines to strengthen the capacity of global" exact="infectious disease" post="surveillance. It may provide useful insights for strategic approaches"/>
  <result pre="its associated disciplines to strengthen the capacity of global infectious" exact="disease" post="surveillance. It may provide useful insights for strategic approaches"/>
  <result pre="projects and improving the capacity for a global response to" exact="infectious disease" post="threats. As aforementioned, the US, the EU, and Japanâ€™s"/>
  <result pre="and improving the capacity for a global response to infectious" exact="disease" post="threats. As aforementioned, the US, the EU, and Japanâ€™s"/>
  <result pre="were retrieved could not cover the study of other serious" exact="infectious diseases" post="such as Zika, Ebola, and Nipah Virus. Supplementary Materials"/>
  <result pre="Table S2: Researches related to platform for immunological response to" exact="viral infection" post="and for vaccine development (Sub-cluster 1-2), Table S3: Platform"/>
  <result pre="S2: Researches related to platform for immunological response to viral" exact="infection" post="and for vaccine development (Sub-cluster 1-2), Table S3: Platform"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins in Korea (Sub-cluster 2-2), Table"/>
  <result pre="and human receptor proteins in Korea (Sub-cluster 2-2), Table S6:" exact="Infectious" post="Disease Epidemiological Investigation &amp;amp; Animal and Environmental Ecology (Cluster"/>
  <result pre="human receptor proteins in Korea (Sub-cluster 2-2), Table S6: Infectious" exact="Disease" post="Epidemiological Investigation &amp;amp; Animal and Environmental Ecology (Cluster 3),"/>
  <result pre="Table S8: Researches related to platform for immunological response to" exact="viral infection" post="and for vaccine development in Korea (Sub-cluster 1-2), Table"/>
  <result pre="S8: Researches related to platform for immunological response to viral" exact="infection" post="and for vaccine development in Korea (Sub-cluster 1-2), Table"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins in Korea (Sub-cluster 2-2), Table"/>
  <result pre="and human receptor proteins in Korea (Sub-cluster 2-2), Table S12:" exact="Infectious" post="Disease Epidemiological Investigation &amp;amp; Animal and Environmental Ecology in"/>
  <result pre="human receptor proteins in Korea (Sub-cluster 2-2), Table S12: Infectious" exact="Disease" post="Epidemiological Investigation &amp;amp; Animal and Environmental Ecology in Korea"/>
  <result pre="Novel CoronavirusWorld Health OrganizationGeneva, Switzerland2020 10.LiJ.-Y.YouZ.WangQ.ZhouZ.-J.QiuY.LuoR.GeX.-Y.The epidemic of 2019-Novel-Coronavirus (2019-NCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the futureMicrobes"/>
  <result pre="10.LiJ.-Y.YouZ.WangQ.ZhouZ.-J.QiuY.LuoR.GeX.-Y.The epidemic of 2019-Novel-Coronavirus (2019-NCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the futureMicrobes Infect.202022808510.1016/j.micinf.2020.02.00232087334 11.PeeriN.C.ShresthaN.RahmanS.TanZ.BibiS.BaghbanzadehM.The SARS, MERS and novel"/>
  <result pre="health threats: What lessons have we learned?Int. J. Epidemiol.202010.1093/ije/dyaa033 12.GreeneC.J.BurlesonS.L.CrosbyJ.C.HeimannM.A.PigottD.C.Coronavirus" exact="disease" post="2019: International public health considerationsJ. Am. Coll. Emerg. Physicians"/>
  <result pre="Coll. Emerg. Physicians Open20201707710.1002/emp2.12040 13.MatthiessenL.LÃ¥ngH.KlimathianakiM.HanrahanF.KerstiÃ«nsB.MartiniA.Draghia-AkliR.European strategy for vaccine development against" exact="infectious" post="diseasesVaccine201735A20A2310.1016/j.vaccine.2016.10.03128017443 14.FitchettJ.R.HeadM.G.CookeM.K.WurieF.B.AtunR.Funding infectious disease research: A systematic analysis of"/>
  <result pre="Open20201707710.1002/emp2.12040 13.MatthiessenL.LÃ¥ngH.KlimathianakiM.HanrahanF.KerstiÃ«nsB.MartiniA.Draghia-AkliR.European strategy for vaccine development against infectious diseasesVaccine201735A20A2310.1016/j.vaccine.2016.10.03128017443 14.FitchettJ.R.HeadM.G.CookeM.K.WurieF.B.AtunR.Funding" exact="infectious disease" post="research: A systematic analysis of UK research investments by"/>
  <result pre="13.MatthiessenL.LÃ¥ngH.KlimathianakiM.HanrahanF.KerstiÃ«nsB.MartiniA.Draghia-AkliR.European strategy for vaccine development against infectious diseasesVaccine201735A20A2310.1016/j.vaccine.2016.10.03128017443 14.FitchettJ.R.HeadM.G.CookeM.K.WurieF.B.AtunR.Funding infectious" exact="disease" post="research: A systematic analysis of UK research investments by"/>
  <result pre="15.HeoY.KangJ.KimK.National scientific funding for interdisciplinary research: A comparison study of" exact="infectious diseases" post="in the US and EUSustain. Switz.201911412010.3390/su11154120 16.ParkS.-C.ParkY.C.Mental health care"/>
  <result pre="18.PanX.OjciusD.M.GaoT.LiZ.PanC.PanC.Lessons learned from the 2019-NCoV epidemic on prevention of future" exact="infectious" post="diseasesMicrobes Infect.202022869110.1016/j.micinf.2020.02.00432088333 19.SweilehW.M.Global research trends of World Health Organizationâ€™s"/>
  <result pre="healthcare-08-00204-t001_Table 1Table 1 The source of global R&amp;amp;D project data." exact="Geographic" post="Region Data Source Search Terms Number of Raw Data"/>
  <result pre="mers-cov * OR sars-cov * OR covid * OR â€œsevere" exact="acute" post="respiratory syndromeâ€� OR â€œmiddle east respiratory syndromeâ€�) 554 228"/>
  <result pre="* OR sars-cov * OR covid * OR â€œsevere acute" exact="respiratory" post="syndromeâ€� OR â€œmiddle east respiratory syndromeâ€�) 554 228 EUâ€&quot;CORDIS"/>
  <result pre="covid * OR â€œsevere acute respiratory syndromeâ€� OR â€œmiddle east" exact="respiratory" post="syndromeâ€�) 554 228 EUâ€&quot;CORDIS 35 10 Japanâ€&quot;KAKEN 10 35"/>
  <result pre="(corona * | sars * | mers *) 638 170" exact="Total" post="(Period: 2012â€&quot;2018) 1237 443 Search terms marked with an"/>
  <result pre="1-1). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 University of Maryland Baltimore Host, pathogen, and"/>
  <result pre="of Maryland Baltimore Host, pathogen, and the microbiome: determinants of" exact="infectious disease" post="outcomes 3,926,048 19,630,240 15 April 2014 31 March 2019"/>
  <result pre="Maryland Baltimore Host, pathogen, and the microbiome: determinants of infectious" exact="disease" post="outcomes 3,926,048 19,630,240 15 April 2014 31 March 2019"/>
  <result pre="University of Iowa Role of eicosanoids in pathogenic human CoV" exact="infections" post="545,235 2,726,175 23 September 2016 31 August 2021 US"/>
  <result pre="Medisch Centrum Rotterdam European management platform for emerging and reemerging" exact="infectious disease" post="entities 3,736,307 18,681,536 1 May 2009 30 April 2014"/>
  <result pre="Centrum Rotterdam European management platform for emerging and reemerging infectious" exact="disease" post="entities 3,736,307 18,681,536 1 May 2009 30 April 2014"/>
  <result pre="Research related to the platform for an immunological response to" exact="viral infection" post="and vaccine development (Sub-Cluster 1-2). NO Organization Title Estimated"/>
  <result pre="related to the platform for an immunological response to viral" exact="infection" post="and vaccine development (Sub-Cluster 1-2). NO Organization Title Estimated"/>
  <result pre="1-2). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 University of North Carolina Chapel Hill Systems"/>
  <result pre="5 August 2012 31 August 2022 US 2 New York" exact="Blood" post="Center Structure-based design of coronavirus subunit vaccines 911,083 4,555,415"/>
  <result pre="September 2012 31 May 2019 US 5 National Institute of" exact="Infectious" post="Diseases The development of a new vaccine against human"/>
  <result pre="2012 31 May 2019 US 5 National Institute of Infectious" exact="Diseases" post="The development of a new vaccine against human coronavirus"/>
  <result pre="of a new vaccine against human coronavirus that causes severe" exact="pneumonia" post="48,100 144,300 1 April 2016 31 March 2019 JP"/>
  <result pre="1-3). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 Columbia University Health Sciences Diagnostic and prognostic"/>
  <result pre="Columbia University Health Sciences Diagnostic and prognostic biomarkers for severe" exact="viral" post="lung disease 1,131,261 5,656,305 7 March 2014 28 February"/>
  <result pre="University Health Sciences Diagnostic and prognostic biomarkers for severe viral" exact="lung disease" post="1,131,261 5,656,305 7 March 2014 28 February 2019 US"/>
  <result pre="Health Sciences Diagnostic and prognostic biomarkers for severe viral lung" exact="disease" post="1,131,261 5,656,305 7 March 2014 28 February 2019 US"/>
  <result pre="EU 5 Nihon University Establishment of gene diagnosis of feline" exact="infectious" post="peritonitis by the analysis of the viral genome 44,200"/>
  <result pre="5 Nihon University Establishment of gene diagnosis of feline infectious" exact="peritonitis" post="by the analysis of the viral genome 44,200 132,600"/>
  <result pre="diagnosis of feline infectious peritonitis by the analysis of the" exact="viral" post="genome 44,200 132,600 1 April 2015 31 March 2018"/>
  <result pre="2-1). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 Blood Systems Research Institute Modeling viral entry"/>
  <result pre="Total Cost (USD) Start Date End Date Geographic Region 1" exact="Blood" post="Systems Research Institute Modeling viral entry and its inhibition"/>
  <result pre="End Date Geographic Region 1 Blood Systems Research Institute Modeling" exact="viral" post="entry and its inhibition using SARS-CoV 406,843 2,034,215 15"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins (Sub-Cluster 2-2). NO Organization Title"/>
  <result pre="2-2). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 University of North Carolina Chapel Hill Broad-spectrum"/>
  <result pre="1 April 2016 31 March 2019 JP healthcare-08-00204-t007_Table 7Table 7" exact="Infectious" post="Disease Epidemiological Investigation and Animal and Environmental Ecology (Cluster"/>
  <result pre="April 2016 31 March 2019 JP healthcare-08-00204-t007_Table 7Table 7 Infectious" exact="Disease" post="Epidemiological Investigation and Animal and Environmental Ecology (Cluster 3)."/>
  <result pre="3). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date Geographic Region 1"/>
  <result pre="Year (USD) Estimated Total Cost (USD) Start Date End Date" exact="Geographic" post="Region 1 George Washington University Ecology of MERS-CoV in"/>
  <result pre="1 September 2017 31 August 2021 US 3 Fred Hutchinson" exact="Cancer" post="Research Center Realtime tracking of virus evolution for vaccine"/>
  <result pre="November 2011 31 October 2016 EU 5 National Institute of" exact="Infectious" post="Diseases The survey of middle east respiratory syndrome coronavirus"/>
  <result pre="2011 31 October 2016 EU 5 National Institute of Infectious" exact="Diseases" post="The survey of middle east respiratory syndrome coronavirus of"/>
  <result pre="National Institute of Infectious Diseases The survey of middle east" exact="respiratory" post="syndrome coronavirus of the dromedary in Ethiopia 137,800 413,400"/>
  <result pre="Institute of Infectious Diseases The survey of middle east respiratory" exact="syndrome" post="coronavirus of the dromedary in Ethiopia 137,800 413,400 1"/>
  <result pre="1-1). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Kookmin University"/>
  <result pre="Mechanistic study on SARS Coronavirus helicase in the process of" exact="viral" post="genome replication 18,272 54,816 1 September 2010 31 August"/>
  <result pre="136,364 1 March 2020 28 February 2023 5 Center for" exact="Disease" post="Control Immunogenocity of SARS-CoV receptor binding protein expressed on"/>
  <result pre="Research related to the platform for the immunological response to" exact="viral infection" post="and for vaccine development in Korea (Sub-Cluster 1-2). NO"/>
  <result pre="related to the platform for the immunological response to viral" exact="infection" post="and for vaccine development in Korea (Sub-Cluster 1-2). NO"/>
  <result pre="1-2). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Seoul National"/>
  <result pre="National University The development of therapeutic antibodies against Middle East" exact="respiratory" post="syndrome coronavirus and Zika virus 99,273 496,364 1 July"/>
  <result pre="University The development of therapeutic antibodies against Middle East respiratory" exact="syndrome" post="coronavirus and Zika virus 99,273 496,364 1 July 2016"/>
  <result pre="3 Korea University Development of next-generation universal vaccine to control" exact="viral" post="infectious diseases 181,818 181,818 1 December 2015 30 November"/>
  <result pre="Korea University Development of next-generation universal vaccine to control viral" exact="infectious diseases" post="181,818 181,818 1 December 2015 30 November 2016 4"/>
  <result pre="181,818 1 December 2015 30 November 2016 4 Center for" exact="Disease" post="Control Expression and immunogenicity study of Coxsackievirus vector of"/>
  <result pre="1-3). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Chonbuk National"/>
  <result pre="customized genetic engineering technology-based approaches for the control of disastrous" exact="infectious diseases" post="53,036 477,328 1 June 2017 28 February 2026 2"/>
  <result pre="87,273 1 January 2019 31 December 2023 5 Center for" exact="Disease" post="Control Development of diagnostic resources for the rapid response"/>
  <result pre="Development of diagnostic resources for the rapid response of emerging" exact="respiratory" post="viruses 181,818 545,455 1 January 2016 31 December 2018"/>
  <result pre="2-1). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Korea Research"/>
  <result pre="1 Korea Research Institute of Bioscience and Biotechnology Development of" exact="viral" post="recombination prediction and validation technique using bioinformatics 30,303 272,727"/>
  <result pre="Seoul National University Simulation study for the prediction of zoonotic" exact="infection" post="risk using genetic variation markers of viruses 26,515 79,545"/>
  <result pre="2017 31 May 2020 4 Kyungdong University Big-data analysis on" exact="viral infection" post="using epigenetic information 48,158 144,475 1 June 2016 31"/>
  <result pre="31 May 2020 4 Kyungdong University Big-data analysis on viral" exact="infection" post="using epigenetic information 48,158 144,475 1 June 2016 31"/>
  <result pre="144,475 1 June 2016 31 May 2019 5 Center for" exact="Disease" post="Control Variation predict and viral attenuation of MERS-CoV 254,545"/>
  <result pre="May 2019 5 Center for Disease Control Variation predict and" exact="viral" post="attenuation of MERS-CoV 254,545 763,636 1 January 2016 31"/>
  <result pre="of antiviral agents based on the structure and function of" exact="viral" post="and human receptor proteins in Korea (Sub-Cluster 2-2). NO"/>
  <result pre="2-2). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Institut Pasteur"/>
  <result pre="candidates for the development of therapeutics in the Middle East" exact="Respiratory" post="Syndrome 152,727 763,636 1 July 2016 31 March 2021"/>
  <result pre="for the development of therapeutics in the Middle East Respiratory" exact="Syndrome" post="152,727 763,636 1 July 2016 31 March 2021 3"/>
  <result pre="of therapeutic target and candidate for immunotherapy against middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) 83,636 418,182 1 July 2016 31"/>
  <result pre="therapeutic target and candidate for immunotherapy against middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) 83,636 418,182 1 July 2016 31 March"/>
  <result pre="83,636 418,182 1 July 2016 31 March 2021 4 Korea" exact="Advanced" post="Institute of Science and Technology Development of novel therapeutics"/>
  <result pre="Institute of Science and Technology Development of novel therapeutics for" exact="infectious diseases" post="through activation of innate immune system 178,182 356,364 1"/>
  <result pre="of recombinant subunit vaccine candidates for the protection against MERS-CoV" exact="infection" post="68,182 272,727 3 December 2015 30 November 2019 healthcare-08-00204-t013_Table"/>
  <result pre="272,727 3 December 2015 30 November 2019 healthcare-08-00204-t013_Table 13Table 13" exact="Infectious" post="disease epidemiological investigation and animal and environmental ecology in"/>
  <result pre="3 December 2015 30 November 2019 healthcare-08-00204-t013_Table 13Table 13 Infectious" exact="disease" post="epidemiological investigation and animal and environmental ecology in Korea"/>
  <result pre="3). NO Organization Title Estimated Average Cost/Fiscal Year (USD) Estimated" exact="Total" post="Cost (USD) Start Date End Date 1 Seoul City"/>
  <result pre="Konkuk University Mathematical models of contact management and spread of" exact="infectious diseases" post="90,909 181,818 7 November 2018 31 December 2019 4"/>
  <result pre="Korea Co., Ltd. Developed mobile sound pressure booths to prevent" exact="secondary" post="infections and medical staff when treating various infectious diseases"/>
  <result pre="Co., Ltd. Developed mobile sound pressure booths to prevent secondary" exact="infections" post="and medical staff when treating various infectious diseases such"/>
  <result pre="to prevent secondary infections and medical staff when treating various" exact="infectious diseases" post="such as MERS 58,237 58,237 1 June 2016 28"/>
 </snippets>
</snippetsTree>
